An interactive association of common sequence variants in the neuropeptide Y gene with susceptibility to ischemic stroke

Stroke

Volumn 38, Issue 10, 2007, Pages 2663-2669

  Lee, Chaeyoung ^a   Kong, Minyoung ^a  

^a Hallym University   (South Korea)

Author keywords

Genetics; Ischemia; Stroke

Indexed keywords

ANGIOTENSINOGEN; BLOOD CLOTTING FACTOR 13A; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; LEUKOCYTE MIGRATION INHIBITION FACTOR; NEUROPEPTIDE Y; PADGEM PROTEIN; PENTRAXIN; PROSTAGLANDIN SYNTHASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEUROPEPTIDE Y; PHENOTYPE; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 34848818557     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.482075     Document Type: Article

References (42)

1. Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease. Stroke. 2006;37:288-290.
2. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke. 2003;34:1364-1369.
3. Kim Y, Lee C. The gene encoding transforming growth factor β1 confers risk of ischemic stroke and vascular dementia. Stroke. 2006;37:2843-2845.
4. Dichgans M, Markus HS. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke. 2005;36:2027-2031.
5. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
6. Seckin D, Ilhan N, Ilhan N, Ozbay Y. The relationship between ACE insertion/deletion polymorphism and coronary artery disease with or without myocardial infarction. Clin Biochem. 2006;39:50-54.
7. Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bodor A, Hadarits F, Melegh B. Coexistence of angiotensin II type-1 receptor A1166C and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke. Neuromolecular Med. 2006;8:353-360.
8. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E, Ruiz-Galdon M, Espinosa-Caliani S, Aranda-Lara P, Rius-Diaz F, Gaitan-Arroyo MJ, De Teresa-Galvan E, Reyes-Engel A. Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction. Clin Genet. 2001;60:52-57.
9. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ, MacMahon S. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet. 1995;345:1600-1603.
10. Szolnoki Z, Havasi V, Talian G, Bene J, Komlosi K, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bodor A, Melegh B. Angiotensin II type-1 receptor A1166C polymorphism is associated with increased risk of ischemic stroke in hypertensive smokers. J Mol Neurosci. 2006;28:285-290.
11. Toda T, Momose Y, Murata M, Tamiya G, Yamamoto M, Hattori N, Inoko H. Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol. 2003;250(suppl):III40-43.
12. Riemenschneider M, Schwarz S, Wagenpfeil S, Diehl J, Muller U, Forstl H, Kurz A. A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the apolipoprotein E epsilon4 allele. Mol Psychiatry. 2002;7:782-785.
13. Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis. 2005;178:193-198.
14. Komanasin N, Catto AJ, Futers TS, van Hylckama Vlieg A, Rosendaal FR, Ariens RA. A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost. 2005;3:2487-2496.
15. Morgan AR, Zhang B, Tapper W, Collins A, Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med. 2003;81:321-326.
16. Zhang S, Mao G, Zhang Y, Tang G, Wen Y, Hong X, Jiang S, Yu Y, Xu X. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension. Clin Ther. 2005;27:1774-1784.
17. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A; Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA. 2004;291:2221-2228.
18. Zee RY, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, Ridker PM. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet. 2004;13:389-396.
19. Boncoraglio GB, Bodini A, Brambilla C, Carriero MR, Ciusani E, Parati EA. An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke. Cerebrovasc Dis. 2006;22:191-195.
20. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005;36:1661-1665.
21. Kim Y, Nam YJ, Lee C. Analysis of the SREBF2 gene as a genetic risk factor for vascular dementia. Am J Med Genet B Neuropsychiatr Genet. 2005;139:19-22.
22. Ameziane N, Seguin C, Borgel D, Fumeron F, Moatti D, Alhenc-Gelas M, Grandchamp B, Aiach M, Emmerich J, de Prost D. The -33T 224 C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb Haemost. 2002;88:195-199.
23. Paciaroni K, Rossi E, Bazzan M, Ireland H, De Stefano V. Prevalence of the C536T mutation in the tissue factor pathway inhibitor (TFPI) gene among patients with venous thromboembolic disease. Thromb Haemost. 2001;85:938-939.
24. Park HY, Nabika T, Jang Y, Kwon HM, Cho SY, Masuda J. Association of G-33A polymorphism in the thrombomodulin gene with myocardial infarction in Koreans. Hypertens Res. 2002;25:389-394.
25. Li YH, Chen JH, Wu HL, Shi GY, Huang HC, Chao TH, Tsai WC, Tsai LM, Guo HR, Wu WS, Chen ZC. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am J Cardiol. 2000;85:8-12.
26. Wu KK, Aleksic N, Ahn C, Boerwinkle E, Folsom AR, Juneja H; Atherosclerosis Risk in Communities Study (ARIC) Investigators. Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation. 2001;103:1386-1389.
27. Hoppe C, Klitz W, Cheng S, Apple R, Steiner L, Robles L, Girard T, Vichinsky E, Styles L; CSSCD Investigators. Gene interactions and stroke risk in children with sickle cell anemia. Blood. 2004;103:2391-2396.
28. Kim Y, Nam YJ, Lee C. Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia. Am J Med Genet B Neuropsychiatr Genet. 2006;141:332-335.
29. Breunis WB, Biezeveld MH, Geissler J, Ottenkamp J, Kuipers IM, Lam J, Hutchinson A, Welch R, Chanock SJ, Kuijpers TW. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum. 2006;54:1588-1594.
30. Richards LJ, Kilpatrick TJ, Dutton R, Tan SS, Gearing DP, Bartlett PF, Murphy M. Leukaemia inhibitory factor or related factors promote the differentiation of neuronal and astrocytic precursors within the developing murine spinal cord. Eur J Neurosci. 1996;8:291-299.
31. Suzuki S, Tanaka K, Nogawa S, Ito D, Dembo T, Kosakai A, Fukuuchi Y. Immunohistochemical detection of leukemia inhibitory factor after focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000;20:661-668.
32. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature. 2001;410:940-944.
33. Michel MC, Rascher W. Neuropeptide Y: a possible role in hypertension? J Hypertens. 1995;13:385-395.
34. Renner W, Grammer T, Hoffmann MM, Nauck MS, Winkelmann BR, Boehm BO, Marz W. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens. 2004;22:2398-2399.
35. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm. 2003;110:1199-1204.
36. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 1992;20:1433.
37. Itokawa M, Arai M, Kato S, Ogata Y, Furukawa A, Haga S, Ujike H, Sora I, Ikeda K, Yoshikawa T. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett. 2003;347:202-204.
38. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MI. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med. 1998;4:1434-1437.
39. Jia C, Liu Z, Liu T, Ning Y. The T1128C polymorphism of neuropeptide Y gene in a Chinese population. Arch Med Res. 2005;36:175-177.
40. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347:1916-1923.
41. Wallerstedt SM, Skrtic S, Eriksson AL, Ohlsson C, Hedner T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens. 2004;22:1277-1281.
42. Erlinge D, Brunkwall J, Edvinsson L. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept. 1994;50:259-265.